Perennial Allergic Rhinitis Drug Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2027

The global perennial allergic rhinitis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Perennial allergic rhinitis is a chronic allergic condition. It causes nasal congestion and a runny nose. Additionally, it doesn't lessen during certain seasons or months of the year. The major factor accelerating the growth of the market is the rising prevalence of perennial allergic rhinitis.

Moreover, the market is also growing due to new product launches. For instance, in January 2021, JB Chemicals and Pharmaceuticals announced that it has received the approval for abbreviated new drug application (ANDA) for Loratadine tablets USP 10 mg from the US FDA in the US market. The drug is used to treat allergic rhinitis caused by pollen and upper respiratory tract allergy. Additionally, in June 2021, Bayer Healthcare LLC announced that it has received the approval of Astepro (azelastine hydrochloride nasal spray, 0.15%) from the US FDA. It is used for the treatment of seasonal and perennial allergic rhinitis for adults and children six years of age and older.

To Request a Sample of our Report on Perennial Allergic Rhinitis Drug Market: https://www.omrglobal.com/request-sample/perennial-allergic-rhinitis-drug-market

Some key players in the market include Merck & Co., Inc., Boehringer Ingelheim GmbH, and Sanofi S.A., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2022, Glenmark Pharmaceuticals Ltd. announced that its fully owned Swiss subsidiary Glenmark Specialty S.A. received approval for Ryaltris, a nasal spray fixed dose prescription drug from the US Food and Drug Administration's (FDA). It is used for the treatment of seasonal allergic rhinitis.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Merck & Co., Inc., Boehringer Ingelheim GmbH, and Sanofi S.A., among others.

(Get 15% Discount on Buying this Report)

A full Report of Perennial Allergic Rhinitis Drug Market is Available @ https://www.omrglobal.com/industry-reports/perennial-allergic-rhinitis-drug-market

Global Perennial Allergic Rhinitis Drug Market Report by Segment

By Type

• APC-3000

• Asapiprant

• Bilastine

• Desloratadine

• Others

By Application

• Clinic

• Hospital

• Others

Global Perennial Allergic Rhinitis Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.